Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs)
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The multi‐billion dollar dietary supplement industry is global in reach. The industry has been criticized for problems related to poor quality control, safety, misbranding, and adulteration. In this review, we describe how the US Food and Drug Administration (FDA) regulates dietary supplements within the framework of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The Dietary Supplement Health and Education Act of 1994 (DSHEA), which amended the FD&C Act, gave the FDA the authority to promulgate Good Manufacturing Practices for dietary supplements and required that manufacturers provide the FDA information supporting a conclusion that the ingredients are reasonably expected to be safe if the dietary ingredients were not marketed in the USA before 15 October 1994. Recent amendments to the FD&C Act require that serious dietary‐supplement‐related adverse events be reported to the FDA and provide the agency with mandatory recall authority. We discuss the presence of naturally occurring (e.g. Ephedra, Citrus aurantium, Acacia) and synthetic (e.g. β‐methylphenethylamines, methylsynephrine, α‐ethyl‐phenethylamine) biologically active phenethylamines (PEAs) in dietary supplements and of PEA drugs (e.g. clenbuterol, fenfluramine, sibutramine, lorcaserin) in weight‐loss products. Regulatory actions against manufacturers of products labelled as dietary supplements that contain the aliphatic amines 1,3‐dimethylamine and 1,3‐dimethylbutylamine, and PEAs such as β‐methylphenethylamine, aegeline, and Dendrobium illustrate the FDA's use of its authority under the FD&C Act to promote dietary supplement safety. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Haller, C. A., & Benowitz, N. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432502 · Cited by 956
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“attack, stroke, resuscitation after cardiac arrest, and cardiovascular death in patients taking sibutramine.([157,158])”
BackgroundMulticenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 2×
“Because of its greater selectivity for the 5-HT2C receptor over the 5-HT2B receptor subtype, the risks of cardiovascular side effects, including heart valve disease, are thought to be low.([169]) Lorcaserin is classified as a Schedule IV drug by the DEA because it is a central nervous system hallucinogen and euphoric…”
BackgroundNutritional supplements cross-contaminated and faked with doping substances
Geyer, H., Parr, M. K., Koehler, K., Mareck, U., Schänzer, W., & Thevis, M. (2008) · Journal of Mass Spectrometry · doi:10.1002/jms.1452 · Cited by 375
Stohs, S. J., Preuss, H. G., & Shara, M. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4446 · Cited by 115 · cited 1×
“There is now a consensus that para- substituted forms are the only forms that occur naturally in bitter orange.([75,76]) However, studies have detected the presence of both para and meta synephrine in bitter orange supplements.”
BackgroundReduction in Ephedra Poisonings after FDA Ban
Zell-Kanter, M., Quigley, M. A., & Leikin, J. B. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1502505 · Cited by 64
Basic Principles of Forensic Chemistry
Khan, J. I., Kennedy, T. J., & Christian, D. R. (2012) · doi:10.1007/978-1-59745-437-7 · Cited by 40 · cited 2×
“Many plants belonging to Cactaceae, Leguminosae, Gnetaceae, and Rutaceae families are known to contain PEA and related compounds.([42]) Many PEAs have stimulant properties but they are rapidly metabolized in the body by monoamine oxidases (MAO).”
BackgroundRat Brain-Uptake Index for Phenylethylamine and Various Monomethylated Derivatives
Mosnaim, A. D., Callaghan, O. H., Hudzik, T., & Wolf, M. E. (2013) · Neurochemical Research · doi:10.1007/s11064-013-0988-1 · Cited by 24
Cited by
Key Challenges for the Commercial Expansion of Ingredients from Algae into Human Food Products
Hosseinkhani, N., McCauley, J. I., & Ralph, P. J. (2022) · Algal Research · doi:10.1016/j.algal.2022.102696 · Cited by 98
Herbal medicines: challenges in the modern world. Part 4. Canada and United States
Job, K. M., Kiang, T. K. L., Constance, J. E., Sherwin, C. M. T., & Enioutina, E. Y. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1238762 · Cited by 38
Metadata
- Authors
- Pawar, R. S., & Grundel, E.
- Venue
- Drug Testing and Analysis
- Publisher
- Wiley
- Published
- 2016-06-03
- Volume
- 9
- Issue
- 3
- Pages
- 500-517
- ISSN
- 1942-7603 (ISSN-L)
- 1942-7611
- OpenAlex
- W2417617302
- Cited by
- 107
- References
- 9
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs). https://app.cochat.ai/papers/10.1002/dta.1980
- The paper
- Pawar, R. S., & Grundel, E. (2017). Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs). Drug Testing and Analysis. https://doi.org/10.1002/dta.1980
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.